HGG-14. RAS PATHWAY MEDIATED REGULATION OF HISTONE METHYLTRANSFERASE AND TUMOR SUPPRESSOR SETD2 IN PEDIATRIC HIGH GRADE GLIOMA

Abstract

Abstract BACKGROUND Pediatric High-Grade Gliomas (pHGG) are a significant cause of cancer-associated deaths in children. Hemispheric pHGG have frequent loss of the NF1 tumor suppressor (15%) causing aberrant RAS pathway activation. Intriguingly, loss of SETD2, a H3K36 methyltransferase, significantly co-occurs with loss of NF1. We found that nearly 80% SETD2-mutant pHGG have inactive NF1 (Pedcbio, 18/23 cases, 78%; odds-ratio 25; FDR adjusted P-value <0.001), suggesting a functional link between SETD2 and RAS signaling. NF1 is a GTPase-activating protein that negatively regulates the RAS oncogenic pathway. SETD2 is an epigenetic regulator and tumor suppressor that tri-methylates H3K36 on active gene bodies during transcription. We found that RAS pathway activation regulates SETD2 function. METHODS First, we used mass spectrometry to identify phosphorylation sites on SETD2 and generated phospho-mimetics/mutants to determine if these sites alter H3K36me3 levels. Second, we assessed if modulating downstream RAS effector pathways with MEK and PI3K inhibitors altered the phosphorylation of identified sites using the PhosTag gel electrophoresis assay. RESULTS We found that T2441 phosphorylation was upregulated upon MEK inhibition and that expressing T2441D phospho-mimetic and T2441A phospho-mutants had a differential effect on global H3K36me3 levels, implicating T2441 as an important regulatory node. Additionally, we identified that Cyclin Dependent Kinases are likely responsible for T2441 phosphorylation and are now investigating how RAS regulates these kinases. CONCLUSION To our knowledge it is the first time a functional connection between RAS pathway activation and SETD2 function has been found. It remains to be seen how of if RAS pathway activation alters the tumor suppressor function of SETD2 in pHGG.